SAREPTA THERAPEUTICS, INC. (SRPT) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 7.06%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 7.06% | Share-based compensation / revenue. Period ending 2026-06-30. $98.81M ÷ $1.40B × 100 ≈ 7.06% |
| Interest coverage · 12 months | (m) | Operating income ÷ reported interest expense. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 1.40B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 98.81M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -143.25M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | -71.63M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.40B | $98.81M | $-143.25M | $-71.63M | (m) | 7.06% | (m) | Reported |
| 2026-03-31 | (m) | $1.58B | $111.37M | $-40.96M | $-55.35M | (m) | 7.03% | (m) | Reported |
| 2025-12-31 | (m) | $1.86B | $123.40M | $-699.78M | $-38.14M | (m) | 6.62% | (m) | Reported |
| 2025-09-30 | (m) | $2.13B | $143.06M | $-126.52M | $-15.01M | (m) | 6.71% | (m) | Reported |
| 2025-06-30 | (m) | $2.19B | $171.58M | $-932.00K | $-17.66M | (m) | 7.83% | (m) | Reported |
| 2025-03-31 | (m) | $2.04B | $185.04M | $-117.21M | $-18.73M | (m) | 9.07% | (m) | Reported |
| 2024-12-31 | (m) | $1.79B | $184.30M | $218.08M | $-18.39M | (m) | 10.31% | (m) | Reported |
| 2024-09-30 | (m) | $1.51B | $180.45M | $81.03M | $19.15M | (m) | 11.91% | 4.23× | Reported |
| 2024-06-30 | (m) | $1.39B | $185.06M | $37.99M | $19.46M | (m) | 13.27% | 1.95× | Reported |
| 2024-03-31 | (m) | $1.27B | $181.96M | $-94.83M | $19.85M | (m) | 14.29% | -4.78× | Reported |
| 2023-12-31 | (m) | $1.14B | $182.51M | $-267.82M | $22.01M | (m) | 15.94% | -12.17× | Reported |
| 2023-09-30 | (m) | $1.02B | $187.20M | $-399.28M | $23.46M | (m) | 18.43% | -17.02× | Reported |
| 2023-06-30 | (m) | $914.19M | $189.56M | $-509.80M | $32.97M | (m) | 20.73% | -15.46× | Reported |
| 2023-03-31 | (m) | $886.44M | $245.07M | $-587.41M | $43.77M | (m) | 27.65% | -13.42× | Reported |
| 2022-12-31 | (m) | $843.77M | $233.02M | $-536.20M | $53.25M | (m) | 27.62% | -10.07× | Reported |
| 2022-09-30 | (m) | $786.56M | $212.29M | $-535.18M | $62.61M | (m) | 26.99% | -8.55× | Reported |
| 2022-06-30 | (m) | $745.70M | $188.56M | $-438.28M | $63.87M | (m) | 25.29% | -6.86× | Reported |
| 2022-03-31 | (m) | $676.30M | $114.63M | $-394.73M | $63.67M | (m) | 16.95% | -6.20× | Reported |
| 2021-12-31 | (m) | $612.40M | $113.94M | $-459.71M | $63.52M | (m) | 18.61% | -7.24× | Reported |
| 2021-09-30 | (m) | $556.32M | $113.69M | $-524.61M | $66.21M | (m) | 20.44% | -7.92× | Reported |
| 2021-06-30 | (m) | $510.84M | $113.91M | $-627.22M | $64.10M | (m) | 22.30% | -9.78× | Reported |
| 2021-03-31 | (m) | $480.34M | $112.55M | $-598.00M | $61.98M | (m) | 23.43% | -9.65× | Reported |
| 2020-12-31 | $722.34M | $455.87M | $108.07M | $-564.16M | $59.95M | 158.46% | 23.71% | -9.41× | Reported |
| 2020-09-30 | (m) | $433.33M | $100.61M | $-623.67M | $49.61M | (m) | 23.22% | -12.57× | Reported |
| 2020-06-30 | (m) | $410.95M | $94.34M | $-610.19M | $43.24M | (m) | 22.96% | -14.11× | Reported |
| 2020-03-31 | (m) | $394.27M | $86.49M | $-747.20M | $36.95M | (m) | 21.94% | -20.22× | Reported |
| 2019-12-31 | $560.91M | $380.83M | $78.60M | $-705.56M | $30.67M | 147.28% | 20.64% | -23.01× | Reported |
| 2019-09-30 | (m) | $365.13M | $69.38M | $-614.71M | $29.53M | (m) | 19.00% | -20.82× | Reported |
| 2019-06-30 | $436.61M | $344.58M | $60.22M | $-561.22M | $32.69M | 126.71% | 17.48% | -17.17× | Reported |
| 2019-03-31 | $446.19M | $323.44M | $55.74M | $-389.28M | $33.41M | 137.95% | 17.23% | -11.65× | Reported |
| 2018-12-31 | $401.84M | $301.03M | $50.13M | $-343.63M | $33.71M | 133.49% | 16.65% | -10.19× | Reported |
| 2018-09-30 | $300.08M | $273.90M | $44.66M | $-227.41M | $30.92M | 109.56% | 16.30% | -7.36× | Reported |
| 2018-06-30 | $247.73M | $241.36M | $40.09M | $-203.22M | $21.04M | 102.64% | 16.61% | -9.66× | Reported |
| 2018-03-31 | $183.79M | $202.85M | $35.28M | $-163.13M | $13.16M | 90.61% | 17.39% | -12.40× | Reported |
| 2017-12-31 | $166.71M | $154.58M | $30.46M | $-171.64M | $5.78M | 107.84% | 19.71% | -29.69× | Reported |
| 2017-09-30 | $193.01M | $102.73M | $29.97M | $-236.89M | (m) | 187.89% | 29.17% | (m) | (m) |
| 2017-06-30 | $193.13M | (m) | $32.47M | $-247.51M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $178.56M | (m) | $28.84M | $-246.27M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $188.27M | $5.42M | $29.96M | $-266.73M | (m) | 3473.01% | 552.70% | (m) | (m) |
| 2016-09-30 | $158.90M | (m) | $29.44M | $-242.79M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $161.22M | (m) | $25.70M | $-238.02M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $146.06M | (m) | $24.80M | $-218.02M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $146.39M | (m) | $32.12M | $-220.18M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $135.85M | (m) | $31.54M | $-200.45M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $121.03M | (m) | $30.50M | $-182.37M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $112.49M | (m) | $30.16M | $-170.53M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $94.23M | (m) | $20.34M | $-133.79M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | $88.47M | (m) | $18.23M | $-121.92M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $87.71M | (m) | $17.07M | $-113.17M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $80.05M | (m) | $13.80M | $-99.99M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $72.91M | (m) | $11.13M | $-90.28M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | $60.67M | (m) | $8.71M | $-67.80M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $50.49M | (m) | $5.92M | $-49.77M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $51.36M | (m) | $4.04M | $-38.24M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $52.40M | (m) | $3.08M | $-29.70M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | $58.27M | (m) | $2.52M | $-28.34M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $62.97M | (m) | $2.42M | $-32.70M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $66.87M | (m) | $2.69M | $-37.27M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $66.86M | (m) | $3.13M | $-35.93M | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $35.97M | (m) | $3.17M | $-20.93M | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $24.40M | (m) | $2.37M | $-15.51M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |